Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension

Benndorf, Ralf A.; Rudolph, Tanja K.; Appel, Daniel; Schwedhelm, Edzard; Maas, Renke; Schulze, Friedrich; Silberhorn, Elisabeth; Böger, Rainer H.

doi:10.1016/j.metabol.2006.04.013

Cited by 95 publications

(70 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Further studies are needed to assess the effect of telmisartan on insulin resistance by hyperinsulinemic euglcyemic glucose clamp. It is noteworthy that other studies reported that telmisartan improves glycemic control and insulin sensitivity without affecting serum adi- (35)(36)(37). In rats fed a high-fat, high-carbohydrate diet, telmisartan treatment promoted increases in caloric expenditure and protected against dietary-induced weight gain (38).…”

Section: Discussionmentioning

confidence: 98%

Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension

et al. 2008

View full text Add to dashboard Cite

Olmesartan lowered mean systolic and diastolic blood pressure more significantly than did telmisartan.While there were no differences between the groups in metabolic parameters, including HbA1c and adiponectin, the decreases in serum interleukin-6 and highly sensitive C-reactive protein were more significant by olmesartan treatment. Our results indicate that olmesartan has more potent arterial blood pressure lowering and anti-inflammatory effects than telmisartan. (Hypertens Res 2008; 31: 7-13)

show abstract

Section: Discussionmentioning

confidence: 98%

Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Telmisartan and irbesartan also improve insulin sensitivity by inducing PPAR-γ activity, an action independent of AT 1 receptor-blocking properties [156][157][158][159][160]. PPAR-γ activation may mediate the induction and prevent the depletion of adiponectin, an adipose-specific protein that enhances insulin sensitivity [161].…”

Section: Mechanismsmentioning

confidence: 99%

Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome

Hayden

Sowers

2008

Journal of the American Society of Hypertension

View full text Add to dashboard Cite

Hypertension, a multifactorial-polygenic disease, interacts with multiple environmental stressors and results in functional and structural changes in numerous end organs, including the cardiovascular system. This can result in coronary heart disease, stroke, peripheral vascular disease, congestive heart failure, end-stage renal disease, insulin resistance, and damage to the pancreatic islet. Hypertension is the most important modifiable risk factor for major health problems encountered in clinical practice. Whereas hypertension was once thought to be a medical condition based on discrete blood pressure readings, a new concept has emerged defining hypertension as part of a complex and progressive metabolic and cardiovascular disease, an important part of a cardiometabolic syndrome. The central role of insulin resistance, oxidative stress, endothelial dysfunction, metabolic signaling defects within tissues, and the role of enhanced tissue renin-angiotensin-aldosterone system activity as it relates to hypertension and type 2 diabetes mellitus is emphasized. Additionally, this review focuses on the effect of hypertension on functional and structural changes associated with the vulnerable pancreatic islet. Various classes of antihypertensive drugs are reviewed, especially their roles in delaying or preventing damage to the vulnerable pancreatic islet, and thus delaying the development of type 2 diabetes mellitus.

show abstract

“…Telmisartan increased leptin levels in diabetic hypertensives, which could have contributed to improved insulin sensitivity in the absence of changes in body weight [51]. Additional clinical trials confirmed the ability of telmisartan to reduce insulin resistance and fasting insulin levels [52,53], and improve pancreatic β cell function [53].…”

Section: Updatementioning

confidence: 88%

Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect?

Ernsberger

Koletsky

2007

Current Opinion in Pharmacology

View full text Add to dashboard Cite

Accumulating basic and clinical data support the hypothesis that angiotensin receptor blockers have beneficial effects on glucose and lipid metabolism that are not shared by other classes of antihypertensive agents. These metabolic actions might only partially be shared by angiotensinconverting enzyme inhibitors. Specific benefits beyond those of other angiotensin receptor blockers have been claimed for telemesartan and, to a lesser extent, irbesartan based on a partial agonist action on PPAR-γ receptors. Although the evidence is strong in vitro, specific actions not shared by other angiotensin receptor blockers have not yet been convincingly demonstrated in vivo or in clinical trials. In many cases, a full range of doses has not been compared, and the apparent superiority of telmesartan could be an artifact of its higher receptor binding affinity, greater tissue penetration owing to lipophilicity, and longer half life.

show abstract

Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension

Cited by 95 publications

References 20 publications

Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension

Comparison of Effects of Olmesartan and Telmisartan on Blood Pressure and Metabolic Parameters in Japanese Early-Stage Type-2 Diabetics with Hypertension

Treating hypertension while protecting the vulnerable islet in the cardiometabolic syndrome

Metabolic actions of angiotensin receptor antagonists: PPAR-γ agonist actions or a class effect?

Contact Info

Product

Resources

About